Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination

• Published in: European journal of surgical oncology Vol. 50; no. 7; p. 108395
• Main Authors: Villarejo Campos, P., Vázquez-Borrego, M.C., Martínez-Quintanilla, J., Cabot, D., Romero-Ruíz, A., Granados-Rodríguez, M., Bura, F.I., García-Arranz, M., García-Olmo, D., Arjona-Sánchez, A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2024
• ISSN: 0748-7983; 1532-2157; 1532-2157
• DOI: 10.1016/j.ejso.2024.108395

The study of circulating tumor DNA (ctDNA) plays a pivotal role in advancing precision oncology, providing valuable information for individualized patient care and contributing to the ongoing effort to improve cancer diagnosis, treatment, and management. However, its applicability in pseudomyxoma peritonei (PMP) remains unexplored. In this multicenter retrospective study involving 21 PMP patients, we investigated ctDNA presence in peripheral blood using three distinct methodologies. Despite mucinous tumor tissues exhibiting KRAS and GNAS mutations, ctDNA for these mutations was undetectable in blood samples. In this pilot study, circulating tumor DNA was not detected in blood when the tumor harbored mutations of known significance. In the future, a study with a larger sample size is needed to confirm these findings and to determine whether ctDNA could identify patients at risk for early recurrence and/or systemic metastases.